





The Therapeutic Drugs Monitoring (TDM) proficiency testing scheme includes clinical samples in therapeutic drugs. The following form contains the calendar of rounds followed by descriptions of the samples and prices.

Please complete all sections below and return to: LGC Standards GmbH, Mercatorstr. 51, 46485 Wesel, Deutschland Tel: +49 (0)281 9887 210, Fax: +49 (0)281 9887 199, E-Mail: axiopt.de@lgcgroup.com

| Returning customer Lab | Purchase order no.: | |
|------------------------|---------------------|--|
| ID: | (compulsory) | |
| | | |

YOUR ORDER

If you would like to renew your order for the same samples/rounds as per previous year, please tick this box:

| R | ΕN | IEV | V I | ME | AS | LAS | ΤΥ | ΈΑΙ |
|---|----|-----|-----|----|----|-----|----|-----|
| | | | | | | | | |

AR

We will copy over the samples/rounds purchased by you in the previous year and send you an order confirmation for your review. If you would like to add any other samples to your order, please mark them accordingly on the subsequent pages.

If you would prefer to place a different/new order for this scheme year, please review the samples available on subsequent pages and indicate the number of samples required for each sample/round accordingly.

SCHEDULE OVERVIEW

| Month | Rollna | Despatch Date | Reporting Deadline | Samples Available |
|-------|--------|------------------|-----------------------|---|
| JAN | AT268 | 05 Jan 2026 | 09 Feb 2026 | 01, 02, 03, 07, AF01 |
| JAN | AT269 | 05 Jan 2026 | 09 Mar 2026 | 01, 02, 03, 07, AF01 |
| JAN | AT270 | 05 Jan 2026 | 07 Apr 2026 | 01, 02, 03, 07, AF01 |
| JAN | TM268 | 19 Jan 2026 | 123 Feb 2026 | 5FU, AE1, AE2, AE4, AE5, AE6, AE7, AH01, AM1, CN1, CRD, PS01, PS02, PS03, PS04, PS05, PS06, PS07, PS08, PS09, PS10, PS11, PS26, PS29, PS32, PS35, PS38, SA01, SA02, TD1 |
| JAN | TM269 | 19 Jan 2026 | 125 War 2026 | AE1, AE2, AE4, AE5, AE6, AE7, CN1, CRD, PS01, PS02, PS03, PS04, PS12, PS13, PS14, PS15, PS16, PS17, PS18, PS27, PS30, PS33, PS39, PST1, SA01, SA02, TD1 |
| JAN | TM270 | 19 Jan 2026 | 120 Anr 2026 | AE1, AE2, AE4, AE5, AE6, AE7, CN1, CRD, NC01, PS01, PS02, PS03, PS04, PS19, PS20, PS21, PS22, PS23, PS24, PS25, PS28, PS31, PS34, PS37, PS40, SA01, SA02, TD1 |
| APR | AT271 | 07 Apr 2026 | 11 May 2026 | 01, 02, 03, 07, AF01 |
| APR | AT272 | 07 Apr 2026 | 08 Jun 2026 | 01, 02, 03, 07, AF01 |
| APR | AT273 | 07 Apr 2026 | 06 Jul 2026 | 01, 02, 03, 07, AF01 |
| APR | TM271 | 27 Apr 2026 | 01 Jun 2026 | 5FU, AE1, AE2, AE4, AE5, AE6, AE7, AH01, AM1, CN1, CRD, PS01, PS02, PS03, PS04, PS05, PS06, PS07, PS08, PS09, PS10, PS11, PS26, PS29, PS32, PS35, PS38, SA01, SA02, TD1 |







| Month | Round | Despatch Date | Reporting Deadline | Samples Available |
|-------|-------|------------------|-----------------------|---|
| APR | TM272 | 27 Apr 2026 | 29 Jun 2026 | AE1, AE2, AE4, AE5, AE6, AE7, CN1, CRD, PS01, PS02, PS03, PS04, PS12, PS13, PS14, PS15, PS16, PS17, PS18, PS27, PS30, PS33, PS39, PS11, SA01, SA02, TD1 |
| APR | TM273 | 27 Apr 2026 | 27 Jul 2026 | AE1, AE2, AE4, AE5, AE6, AE7, CN1, CRD, NC01, PS01, PS02, PS03, PS04, PS19, PS20, PS21, PS22, PS23, PS24, PS25, PS28, PS31, PS34, PS37, PS40, SA01, SA02, TD1 |
| JUN | AT274 | 29 Jun 2026 | 03 Aug 2026 | 01, 02, 03, 07, AF01 |
| JUN | AT275 | 29 Jun 2026 | 01 Sep 2026 | 01, 02, 03, 07, AF01 |
| JUN | AT276 | 29 Jun 2026 | 28 Sep 2026 | 01, 02, 03, 07, AF01 |
| JUL | TM274 | 20 Jul 2026 | 24 Aug 2026 | 5FU, AE1, AE2, AE4, AE5, AE6, AE7, AH01, AM1, CN1, CRD, PS01, PS02, PS03, PS04, PS05, PS06, PS07, PS08, PS09, PS10, PS11, PS26, PS29, PS32, PS35, PS38, SA01, SA02, TD1 |
| JUL | TM275 | 20 Jul 2026 | 21 Sep 2026 | AE1, AE2, AE4, AE5, AE6, AE7, CN1, CRD, PS01, PS02, PS03, PS04, PS12, PS13, PS14, PS15, PS16, PS17, PS18, PS27, PS30, PS33, PS39, PS11, SA01, SA02, TD1 |
| JUL | TM276 | 20 Jul 2026 | 19 Oct 2026 | AE1, AE2, AE4, AE5, AE6, AE7, CN1, CRD, NC01, PS01, PS02, PS03, PS04, PS19, PS20, PS21, PS22, PS23, PS24, PS25, PS28, PS31, PS34, PS37, PS40, SA01, SA02, TD1 |
| SEP | AT277 | 28 Sep 2026 | 02 Nov 2026 | 01, 02, 03, 07, AF01 |
| SEP | AT278 | 28 Sep 2026 | 30 Nov 2026 | 01, 02, 03, 07, AF01 |
| SEP | AT279 | 28 Sep 2026 | 11 Jan 2027 | 01, 02, 03, 07, AF01 |
| ост | TM277 | 26 Oct 2026 | 30 Nov 2026 | 5FU, AE1, AE2, AE4, AE5, AE6, AE7, AH01, AM1, CN1, CRD, PS01, PS02, PS03, PS04, PS05, PS06, PS07, PS08, PS09, PS10, PS11, PS26, PS29, PS32, PS35, PS38, SA01, SA02, TD1 |
| ост | TM278 | 26 Oct 2026 | 04 Jan 2027 | AE1, AE2, AE4, AE5, AE6, AE7, CN1, CRD, PS01, PS02, PS03, PS04, PS12, PS13, PS14, PS15, PS16, PS17, PS18, PS27, PS30, PS33, PS39, PST1, SA01, SA02, TD1 |
| ост | TM279 | 26 Oct 2026 | 25 Jan 2027 | AE1, AE2, AE4, AE5, AE6, AE7, CN1, CRD, NC01, PS01, PS02, PS03, PS04, PS19, PS20, PS21, PS22, PS23, PS24, PS25, PS28, PS31, PS34, PS37, PS40, SA01, SA02, TD1 |

Please ensure that LGC receive your order as soon as possible in order to avoid stock shortages. Please note that orders received the week prior to the despatch date may be subject to a despatch delay.

The despatch date shown above is the date the sample will leave our site in the UK. Please note, this is not the date the samples will arrive at your laboratory. Delivery times vary based on country, if you require further information, please contact LGC.







SAMPLE AVAILABILITY – PLEASE SEE PAGE 1 FOR SPECIFIC DESPATCH AND REPORTING DATES

Please indicate the required samples in the grid.

Please note: Where a footnote symbol ($* | # | ^ | †$) appears in a column, the footnote description text may appear at the end of a table that may span across multiple pages. Please scroll to the end of the table for these details.

| Therapeutic Drugs | | | | | |
|-------------------|--|--|------------------------------|-----------------------------|--|
| Sample | Supplied As | Target Analytes | Rounds available per year | All Rounds (Please tick) | |
| PT-TM-TD01 | 3 x 5ml samples of lyophilised human serum | Carbamazepine; CBZ-epoxide; Carbamazepine + CBZ-epoxide; Clonazepam; Lamotrigine; Phenytoin; Ethosuximide; Phenobarbitone; Primidone; Valproate; Caffeine; Digoxin; Lithium; Theophylline; Methotrexate; Paracetamol (Acetaminophen); Salicylic Acid; TD-Amikacin; TD-Gentamicin; TD-Tobramycin; TD-Vancomycin | 12 | | |

| Other Therapeutic Drugs | | | | | |
|-------------------------|--|---|------------------------------|--------------------------|--|
| Sample | Supplied As | Target Analytes | Rounds available per year | All Rounds (Please tick) | |
| PT-TM-AE01 | 1 x 4ml sample of lyophilised human serum | OH-oxcarbazepine; Gabapentin; Tiagabine; Levetiracetam; Pregabalin | 12 | | |
| PT-TM-AE02 | 1 x 4ml sample of lyophilised human serum | Topiramate; Vigabatrin; Felbamate; Zonisamide; Rufinamide; Lacosamide | 12 | | |
| PT-TM-AE04* | 1 x 2ml sample of lyophilised human serum | Perampanel | 12 | | |
| PT-TM-AE05* | 1 x 2ml sample of lyophilised human serum | Brivaracetam | 12 | | |
| PT-TM-AE6* | 1 x 2ml sample of lyophilised human serum | Stiripentol | 12 | | |
| PT-TM-AE7* | 1 x 2ml sample of lyophilised human serum | Sulthiame | 12 | | |







| | | Other Therapeutic Drugs | | Rounds (TM) |
|------------------------------|---|--|------------------------------|--------------------------|
| Sample | Supplied As | Target Analytes | Rounds available per year | All Rounds (Please tick) |
| PT-TM-AMO1* | 2 x 5ml sample of lyophilised human serum | Ibuprofen; Diclofenac; Tramadol; O-Desmethyltramadol | 4 | |
| PT-TM-CN01 | 2 x 2ml samples of lyophilised human serum | Clobazam; Norclobazam | 12 | |
| PT-TM-CRD Cardiac mixture | 1 x 2ml sample of lyophilised human serum | Amiodarone; Desethylamiodarone; Flecainide | 12 | |

^{*}These samples are not currently included in LGC's UKAS Scope of Accreditation.

| | Drugs for Treatment of substance related disorders | | | | |
|--|--|---------------------------------|------------------------------|--------------------------|--|
| Sample | Supplied As | Target Analytes | Rounds available per year | All Rounds (Please tick) | |
| PT-TM-SA01 Drugs for the Treatment of substance related disorders 1 | | Buprenorphine; Norbuprenorphine | 12 | | |
| PT-TM-SA02 Drugs for the Treatment of substance related disorders 2 | | Methadone; EDDP | 12 | | |

| Anti-Hypertensive Drug Screen | | | | |
|---|-------------|---|------------------------------|--------------------------|
| Sample | Supplied As | Target Analytes | Rounds available per year | All Rounds (Please tick) |
| PT-TM-AH01 * Anti- Hypertensive in Urine | | Drug identification. Up to four drugs may be present in the sample, please see the TDM scheme description for further details | 4 | |

^{*}These samples are not currently included in LGC's UKAS Scope of Accreditation.







| | Che | Rounds (TM) | | |
|-----------------|----------------------------------|-----------------|------------------------------|--------------------------|
| Sample | Supplied As | Target Analytes | Rounds available per year | All Rounds (Please tick) |
| PT-TM-5FU * NEW | 2 x 5ml lyophilised human plasma | 5-Fluorouracil | 4 | |

^{*}These samples are not currently included in LGC's UKAS Scope of Accreditation.

| | | Rounds (TM) | | |
|------------|--|-------------------------------|------------------------------|--------------------------|
| Sample | Supplied As | Target Analytes | Rounds available per year | All Rounds (Please tick) |
| PT-TM-PS01 | 1 x 5ml sample of lyophilised newborn calf serum or human serum | Amitriptyline; Nortriptyline | 12 | |
| PT-TM-PS02 | 1 x 5ml sample of lyophilised newborn calf serum or human serum | Imipramine; Desipramine | 12 | |
| PT-TM-PS03 | 1 x 5ml sample of lyophilised newborn calf serum or human serum | Clomipramine; Norclomipramine | 12 | |
| PT-TM-PS04 | 1 x 5ml sample of lyophilised newborn calf serum or human serum | Clozapine; Norclozapine | 12 | |
| PT-TM-PS05 | 1 x 5ml sample of lyophilised newborn calf serum or human serum | Doxepin; Nordoxepin | 4 | |
| PT-TM-PS06 | 1 x 5ml sample of lyophilised newborn calf serum or human serum | Fluoxetine; Norfluoxetine | 4 | |
| PT-TM-PS07 | 1 x 5ml sample of lyophilised newborn calf serum or human serum | Fluphenazine | 4 | |
| PT-TM-PS08 | 1 x 5ml sample of lyophilised newborn calf serum or human serum | Sertraline; Norsertraline | 4 | |







| | | Psychoactive Drugs | | Rounds (TM) |
|------------|---|-------------------------------|------------------------------|--------------------------|
| Sample | Supplied As | Target Analytes | Rounds available per year | All Rounds (Please tick) |
| PT-TM-PS09 | 1 x 5ml sample of lyophilised newborn calf serum or human serum | Trimipramine; Nortrimipramine | 4 | |
| PT-TM-PS10 | 1 x 5ml sample of lyophilised newborn calf serum or human serum | Risperidone; HO-risperidone | 4 | |
| PT-TM-PS11 | 1 x 5ml sample of lyophilised newborn calf serum or human serum | Mirtazapine; Normirtazapine | 4 | |
| PT-TM-PS12 | 1 x 5ml sample of lyophilised newborn calf serum or human serum | Maprotiline | 4 | |
| PT-TM-PS13 | 1 x 5ml sample of lyophilised newborn calf serum or human serum | Thioridazine | 4 | |
| PT-TM-PS14 | 1 x 5ml sample of lyophilised newborn calf serum or human serum | Haloperidol | 4 | |
| PT-TM-PS15 | 1 x 5ml sample of lyophilised newborn calf serum or human serum | Olanzapine; Norolanzapine | 4 | |
| PT-TM-PS16 | 1 x 5ml sample of lyophilised newborn calf serum or human serum | Perphenazine | 4 | |
| PT-TM-PS17 | 1 x 5ml sample of lyophilised newborn calf serum or human serum | Quetiapine; Norquetiapine | 4 | |
| PT-TM-PS18 | 1 x 5ml sample of lyophilised newborn calf serum or human serum | Citalopram; Norcitalopram | 4 | |







| | | Psychoactive Drugs | | Rounds (TM) |
|------------|--|-----------------------------------|------------------------------|--------------------------|
| Sample | Supplied As | Target Analytes | Rounds available per year | All Rounds (Please tick) |
| PT-TM-PS19 | 1 x 5ml sample of lyophilised newborn calf serum or human serum | Dothiepin; Northiaden | 4 | |
| PT-TM-PS20 | 1 x 5ml sample of lyophilised newborn calf serum or human serum | Venlafaxine; Norvenlafaxine | 4 | |
| PT-TM-PS21 | 1 x 5ml sample of lyophilised newborn calf serum or human serum | Paroxetine | 4 | |
| PT-TM-PS22 | 1 x 5ml sample of lyophilised newborn calf serum or human serum | Fluvoxamine | 4 | |
| PT-TM-PS23 | 1 x 5ml sample of lyophilised newborn calf serum or human serum | Zuclopenthixol | 4 | |
| PT-TM-PS24 | 1 x 5ml sample of lyophilised newborn calf serum or human serum | Amisulpride | 4 | |
| PT-TM-PS25 | 1 x 5ml sample of lyophilised newborn calf serum or human serum | Aripiprazole; Dehydroaripiprazole | 4 | |
| PT-TM-PS26 | 1 x 5ml sample of lyophilised newborn calf serum or human serum | Ziprasidone | 4 | |
| PT-TM-PS27 | 1 x 5ml sample of lyophilised newborn calf serum or human serum | Duloxetine | 4 | |
| PT-TM-PS28 | 1 x 5ml sample of lyophilised newborn calf serum or human serum | Escitalopram | 4 | |







| | | Psychoactive Drugs | | Rounds (TM) |
|--------------|--|-----------------------------|------------------------------|--------------------------|
| Sample | Supplied As | Target Analytes | Rounds available per year | All Rounds (Please tick) |
| PT-TM-PS29 | l x 5ml sample of lyophilised newborn calf serum or human serum | Trazodone | 4 | |
| PT-TM-PS30 | 1 x 5ml sample of lyophilised newborn calf serum or human serum | Sulpiride | 4 | |
| PT-TM-PS31* | 1 x 5ml sample of lyophilised newborn calf serum or human serum | Chlorpromazine | 4 | |
| PT-TM-PS32 * | 1 x 5ml sample of lyophilised newborn calf serum or human serum | Mianserin | 4 | |
| PT-TM-PS33 * | 1 x 5ml sample of lyophilised newborn calf serum or human serum | Brexpiprazole | 4 | |
| PT-TM-PS34* | 1 x 5ml sample of lyophilised newborn calf serum or human serum | Lurasidone | 4 | |
| PT-TM-PS35 * | 1 x 5ml sample of lyophilised newborn calf serum or human serum | Sertindole | 4 | |
| PT-TM-PS37 * | 1 x 5ml sample of lyophilised newborn calf serum or human serum | Vortioxetine | 4 | |
| PT-TM-PS38 * | 1 x 5ml sample of lyophilised newborn calf serum or human serum | Meclobemide | 4 | |
| PT-TM-PS39 * | 1 x 5ml sample of lyophilised newborn calf serum or human serum | Bupropion; Hydroxybupropion | 4 | |







| | | Rounds (TM) | | |
|--------------|--|-----------------|------------------------------|--------------------------|
| Sample | Supplied As | Target Analytes | Rounds available per year | All Rounds (Please tick) |
| PT-TM-PS40 * | 1 x 5ml sample of lyophilised newborn calf serum or human serum | Flupentixol | 4 | |

^{*}These samples are not currently included in LGC's UKAS Scope of Accreditation.

†Please note that a volume discount may apply to this price, depending on the number of Therapeutic Drugs Monitoring (TDM) PT Scheme samples purchased. For further details, please see the Volume Quantity Discount section.

| Psychostimulants | | | | Rounds (TM) |
|------------------|---------------------------------|--|------------------------------|--------------------------|
| Sample | Supplied As | Target Analytes | Rounds available per year | All Rounds (Please tick) |
| PT-TM-PST1* | 2 x 5ml lyophilised human serum | Atomoxetine; Methylphenidate; Ritalinic acid | 4 | |

^{*}These samples are not currently included in LGC's UKAS Scope of Accreditation.

| Smoking Related Drugs | | | Rounds (TM) | |
|-----------------------|---------------------------------|--------------------|------------------------------|--------------------------|
| Sample | Supplied As | Target Analytes | Rounds available per year | All Rounds (Please tick) |
| PT-TM-NC01* | 2 x 5ml lyophilised human urine | Nicotine; Cotinine | 4 | |

^{*}These samples are not currently included in LGC's UKAS Scope of Accreditation.

| Antibiotic and Antifungal Drugs | | | Rounds (TM) | | |
|---------------------------------|----------|---------------------|------------------------|------------------------------|--------------------------|
| | Sample | Supplied As | Target Analytes | Rounds available per year | All Rounds (Please tick) |
| | PT-AT-01 | 1 x 1m1 human serum | Gentamicin; Vancomycin | 12 | |
| | PT-AT-02 | 1 x 1m1 human serum | Tobramycin | 12 | |







| Antibiotic and Antifungal Drugs | | | | |
|---------------------------------|------------------------|---|------------------------------|--------------------------|
| Sample | Supplied As | Target Analytes | Rounds available per year | All Rounds (Please tick) |
| PT-AT-03 | 1 x 1m1 human serum | Amikacin | 12 | |
| PT-AT-07 | 1 x 1ml human serum | Teicoplanin | 12 | |
| PT-AT-AF01* | 1 x 1.7 ml human serum | Posaconazole; Voriconazole; Itraconazole; OH-Itraconazole; Fluconazole; Isavuconazole | 12 | |

^{*}These samples are not currently included in LGC's UKAS Scope of Accreditation.

Please note that all accredited samples are accredited within the boundaries of LGC's fixed and flexible scope of UKAS accreditation. For further details and the full technical specification of the scheme, please refer to the Scheme Description

To access our General Protocol, covering our scheme organisation and operation, test materials, reporting of results, data analysis/performance assessment and information provided to participants, please click on the following link: GENERAL PROTOCOL – PT Schemes







YOUR DETAILS

| Returning customers, if you would like to keep your contact/address details as per previous | JS |
|---|----|
| year, please tick here: | |

| Г | | 1 |
|---|--|---|
| l | | |
| l | | |
| l | | |

If changes are required or you are a new customer, please complete your details below:

| Send Test Materials to: | Send Invoices to: | | | |
|---|-------------------|--|--|--|
| Contact name: | Contact name: | | | |
| Department: | Department: | | | |
| Company: | Company: | | | |
| Address: | Address: | | | |
| | | | | |
| Town/City: | Town/City: | | | |
| County: | County: | | | |
| Post/Zip Code: | Post/Zip Code: | | | |
| Country: | Country: | | | |
| Tel: | Tel: | | | |
| E-mail: | E-mail: | | | |
| | VAT no: | | | |
| New customers LGC would like to contact you by email, phone or post about its products, services and related areas or research. LGC does not sell contact details to external parties. You may unsubscribe at any time. Yes, I am happy to be contacted about LGC's products, services and research No, I do not require marketing information about LGC's products and services at this time | | | | |
| By sending in this application form, you are agreeing to comply by LGC's Standard Terms and Conditions for the Supply of Laboratory Quality Products and Services and are agreeing that you have read and agree to the 'General Notes' at the end of this document. Name Date | | | | |







VOLUME QUANTITY DISCOUNT

Please note that any additional/duplicate samples ordered will not contribute to the calculation of volume discount, but will be charged at a lower rate (see Repeat/Additional samples section).

| Psychoactive Drugs samples purchased per order | Volume Discount |
|--|-----------------|
| 1-5 | 0% |
| 6-10 | 5% |
| 11-15 | 10% |
| 16+ | 15% |

REPEAT/ADDITIONAL SAMPLES PRICES

For repeat/additional samples, please contact LGC for a quotation.

CARRIAGE CHARGES

Participants will pay an additional fee to cover courier charges. Please contact LGC AXIO Proficiency Testing for up-to-date charges.

CHANGES AND OTHER SCHEMES/SAMPLES OF INTEREST

CHANGES

We have introduced a new sample as follows:

Sample PT-TM-5FU (5-Fluorouracil). This will be available quarterly.

We have removed the analyte Norchlorpromazine from sample PT-TM-PS31 (Chlorpromazine)

OTHER SCHEMES/SAMPLES OF INTEREST

We have a number of other Clinical schemes available which may be of interest to you. Further details can be found on our Clinical schemes webpage

GENERAL NOTES

Please note:

- All prices stated are exclusive of VAT and carriage charges.
- VAT (charged at the prevailing rate) is payable by all participants based in the European Union if a VAT Registration Number is not provided.
- Participants will pay an additional fee to cover courier charges. Please contact LGC AXIO Proficiency Testing for up-to-date charges (where not specified previously in the application form).
- All courier charges set by LGC AXIO Proficiency Testing do not include local import charges, taxes (etc.), which will be covered by the participant.
- Do not send remittance with this form, you will be invoiced subsequently after the despatch of each round.
- No refunds will be given for failure to take part in any round of the PT scheme.
- LGC AXIO Proficiency Testing reserves the right to not send samples or the report for previous samples to any participant that has not paid their subscriptions within the terms stated on the invoice.
- LGC AXIO Proficiency Testing cannot guarantee the number of participants that will return results for any particular parameter in each round.
- The prices stated are for reporting results and receiving reports electronically via PORTAL (internet reporting).
- Surplus PT samples (Quality Control Material) are available; please contact LGC AXIO Proficiency Testing for further information.







• By submitting this application form, you are agreeing to comply by LGC's Standard Terms and Conditions for the Supply of Laboratory Quality Products and Services.

LGC AXIO PT FOR INTERNAL USE ONLY

| Name | |
|-------------|--|
| Customer | |
| Site | |
| Currency | |
| Address ID | |
| PO no | |
| Carriage | |
| Renew ALY | |
| Year for PY | |

| Dt | |
|--------------------|--|
| Doc Text | |
| Quotation | |
| Co-ordinator | |
| Case Number | |
| Case Email Address | |
| Contact Name | |
| Template Name | |
| Additional | |